{"id":221118,"date":"2025-08-29T00:16:39","date_gmt":"2025-08-29T05:16:39","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/08\/biomarker-brings-er-breast-cancer-patients-one-step-closer-to-more-personalized-therapy"},"modified":"2025-08-29T00:16:39","modified_gmt":"2025-08-29T05:16:39","slug":"biomarker-brings-er-breast-cancer-patients-one-step-closer-to-more-personalized-therapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/08\/biomarker-brings-er-breast-cancer-patients-one-step-closer-to-more-personalized-therapy","title":{"rendered":"Biomarker brings ER+ breast cancer patients one step closer to more personalized therapy"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/biomarker-brings-er-breast-cancer-patients-one-step-closer-to-more-personalized-therapy2.jpg\"><\/a><\/p>\n<p>A new study by researchers at Baylor College of Medicine brings hope for a more personalized approach to treating estrogen receptor-positive (ER+) breast cancer, the most common type of this cancer. The team identified a biomarker in preclinical ER+ breast cancer models that indicates that the tumor is more likely to respond to treatment with CDK4\/6 inhibitors.<\/p>\n<p>The findings support further clinical studies to determine whether this marker may help identify patients who could benefit from CDK4\/6 inhibitors. The study appears in Science Translational Medicine.<\/p>\n<p>ER+ breast cancers rely on estrogen to grow and are typically treated by endocrine therapies that block the effects of estrogen. To improve outcomes, drugs called CDK4\/6 inhibitors, such as abemaciclib and ribociclib, are added to endocrine therapy to prevent relapse.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study by researchers at Baylor College of Medicine brings hope for a more personalized approach to treating estrogen receptor-positive (ER+) breast cancer, the most common type of this cancer. The team identified a biomarker in preclinical ER+ breast cancer models that indicates that the tumor is more likely to respond to treatment with [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-221118","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/221118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=221118"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/221118\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=221118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=221118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=221118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}